CN101505744A - 用于预防和治疗眼部病症的内皮分化基因亚家庭3（edg-3，s1p3）受体的拮抗剂 - Google Patents

用于预防和治疗眼部病症的内皮分化基因亚家庭3（edg-3，s1p3）受体的拮抗剂 Download PDF

Info

Publication number
CN101505744A
CN101505744A CNA2007800311386A CN200780031138A CN101505744A CN 101505744 A CN101505744 A CN 101505744A CN A2007800311386 A CNA2007800311386 A CN A2007800311386A CN 200780031138 A CN200780031138 A CN 200780031138A CN 101505744 A CN101505744 A CN 101505744A
Authority
CN
China
Prior art keywords
antagonist
alkyl
experimenter
receptor
glaucoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800311386A
Other languages
English (en)
Chinese (zh)
Inventor
D·L·弗里诺尔
A·R·谢帕德
彭玉豪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Research LLC
Original Assignee
Alcon Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Research LLC filed Critical Alcon Research LLC
Publication of CN101505744A publication Critical patent/CN101505744A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2007800311386A 2006-07-25 2007-07-25 用于预防和治疗眼部病症的内皮分化基因亚家庭3（edg-3，s1p3）受体的拮抗剂 Pending CN101505744A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83308006P 2006-07-25 2006-07-25
US60/833,080 2006-07-25

Publications (1)

Publication Number Publication Date
CN101505744A true CN101505744A (zh) 2009-08-12

Family

ID=38982306

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800311386A Pending CN101505744A (zh) 2006-07-25 2007-07-25 用于预防和治疗眼部病症的内皮分化基因亚家庭3（edg-3，s1p3）受体的拮抗剂

Country Status (11)

Country Link
US (2) US20080025973A1 (enExample)
EP (1) EP2068856A2 (enExample)
JP (1) JP2009544734A (enExample)
KR (1) KR20090033886A (enExample)
CN (1) CN101505744A (enExample)
AU (1) AU2007279311A1 (enExample)
BR (1) BRPI0714593A2 (enExample)
CA (1) CA2657480A1 (enExample)
MX (1) MX2009000907A (enExample)
WO (1) WO2008014338A2 (enExample)
ZA (1) ZA200900316B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005264431B2 (en) * 2004-07-16 2010-08-19 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect
PT2511262T (pt) 2004-10-12 2017-03-30 Kyorin Seiyaku Kk Processo para a produção de cloridrato de 2-amino-2-[2-[4-(3- benziloxi-feniltio)-2-clorofenil[etil]-1,3-propanodiol
BRPI0617077A2 (pt) * 2005-10-07 2015-01-06 Kyorin Seiyaku Kk Agente terapêutico para tratamento de doenças do fígado contendo 2-amina-1, 3-propanediol derivativo como ingrediente ativo, e método para tratamento de doenças do fígado
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
NZ574011A (en) * 2006-08-08 2011-10-28 Kyorin Seiyaku Kk Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient
CA2659599C (en) * 2006-08-08 2014-06-17 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative and immunosuppressive agent having same as an active ingredient
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
US20110009453A1 (en) * 2008-03-17 2011-01-13 Donello John E s1p3 receptor inhibitors for treating inflammation
WO2010129553A1 (en) * 2009-05-05 2010-11-11 Allergan, Inc. S1p3 receptor inhibitors for treating conditions of the eye
RU2012105453A (ru) * 2009-08-11 2013-09-20 Аллерган, Инк. Изотиозолы для лечения состояний глаз
WO2011038446A1 (en) * 2009-09-30 2011-04-07 Stiefel Research Australia Pty Ltd Cosmetic foam
CN102146411B (zh) * 2011-01-06 2013-01-02 中国人民解放军第三军医大学第三附属医院 新型双功能抗瘢痕和组织纤维化寡聚核苷酸药物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013811A1 (de) * 1993-11-17 1995-05-26 Byk Nederland Bv Verwendung substituierter thiazolidinderivate zur behandlung von erhöhtem augeninnendruck
US5545626A (en) * 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
US5750652A (en) * 1994-01-21 1998-05-12 Yale University Deltex proteins
EP1253929B1 (en) * 2000-02-09 2007-05-23 BAS Medical, Inc. Use of relaxin to treat diseases related to vasoconstriction
JP2001261575A (ja) * 2000-03-13 2001-09-26 General Hospital Corp 血管収縮を調節する方法とその組成物
JP2002332278A (ja) * 2001-05-08 2002-11-22 Human Science Shinko Zaidan Ｅｄｇ受容体拮抗作用を有する複素環誘導体
KR20040104566A (ko) * 2002-04-30 2004-12-10 알콘, 인코퍼레이티드 안압 저하 및 녹내장성 망막병증/시신경병증 치료를 위한특유의 수단으로서의 결합 조직 성장 인자 (ｃｔｇｆ)의활성 및/또는 발현 조절, 저해, 또는 변조제
EP1546110A4 (en) * 2002-07-30 2008-03-26 Univ Virginia COMPOUNDS WITH EFFECT ON SIGNAL TRANSMISSION BY SPHINGOSINE-1-PHOSPHATE
CA2495917A1 (en) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
FR2845003A1 (fr) * 2002-09-30 2004-04-02 Merck Sante Sas Utilisation de derives de thiazolidinedione comme inhibiteurs de l'aldose reductase
US20060173046A1 (en) * 2003-07-15 2006-08-03 Bell Ian M Hydroxypyridine cgrp receptor antagonists
JP2005247691A (ja) * 2004-03-01 2005-09-15 Toa Eiyo Ltd Ｓ１ｐ３受容体拮抗薬
US7888527B2 (en) * 2004-12-06 2011-02-15 University Of Virginia Patent Foundation Aryl amide sphingosine 1-phosphate analogs
EP1935874A4 (en) * 2005-10-12 2010-10-13 Toa Eiyo Ltd S1P3 RECEPTOR ANTAGONIST
CN101460458A (zh) * 2006-02-15 2009-06-17 阿勒根公司 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物

Also Published As

Publication number Publication date
ZA200900316B (en) 2010-05-26
JP2009544734A (ja) 2009-12-17
CA2657480A1 (en) 2008-01-31
US20080025973A1 (en) 2008-01-31
US20100183629A1 (en) 2010-07-22
WO2008014338A3 (en) 2008-12-24
MX2009000907A (es) 2009-02-04
EP2068856A2 (en) 2009-06-17
WO2008014338A2 (en) 2008-01-31
BRPI0714593A2 (pt) 2013-05-07
AU2007279311A1 (en) 2008-01-31
KR20090033886A (ko) 2009-04-06

Similar Documents

Publication Publication Date Title
CN101505744A (zh) 用于预防和治疗眼部病症的内皮分化基因亚家庭3（edg-3，s1p3）受体的拮抗剂
EP2262476B1 (en) Drug delivery to the anterior and posterior segments of the eye using eye drops.
Tokushige et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
RU2370267C2 (ru) Антагонисты cdk2 в качестве антагонистов короткой формы фактора транскрипции c-maf для лечения глаукомы
US20040213782A1 (en) Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure
JP4482726B2 (ja) Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
US20110105574A1 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
US20100247548A1 (en) Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders
Zhan et al. Bunazosin reduces intraocular pressure in rabbits by increasing uveoscleral outflow
WO2022034909A1 (ja) セペタプロストを含有する医薬製剤
Mokbel et al. Rho-Kinase Inhibitors as a novel medication for Glaucoma Treatment–A Review of the literature
JP7580123B2 (ja) 血管新生関連疾患の予防又は治療用医薬組成物
US20070232675A1 (en) Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
US20210363247A1 (en) Novel Treatments of Glaucoma
Virani et al. An Update on Pharmacotherapy of Glaucoma
US20150284393A1 (en) Methods for treating eye disorders
JP2025061389A (ja) 細胞外マトリックス調節剤
AU2013204371A1 (en) Treatment of Ocular Diseases
CN117224546A (zh) Cz415在制备降眼压药物上的应用
WO2020166679A1 (ja) 眼圧下降用医薬組成物
US20100158897A1 (en) Pai-1 modulators for the treatment of ocular disorders
JP2004189735A (ja) Ｌｉｍキナーゼ阻害作用を有する化合物を有効成分とする緑内障治療剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090812